Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · IEX Real-Time Price · USD
3.770
+0.130 (3.57%)
At close: May 3, 2024, 4:00 PM
3.700
-0.070 (-1.86%)
After-hours: May 3, 2024, 7:09 PM EDT
Caribou Biosciences Revenue
In the year 2023, Caribou Biosciences had annual revenue of $34.48M with 148.91% growth. Revenue in the quarter ending December 31, 2023 was $3.56M, a -3.63% decrease year-over-year.
Revenue (ttm)
$34.48M
Revenue Growth
+148.91%
P/S Ratio
9.88
Revenue / Employee
$218,209
Employees
158
Market Cap
340.50M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 34.48M | 20.63M | 148.91% |
| Dec 31, 2022 | 13.85M | 4.25M | 44.31% |
| Dec 31, 2021 | 9.60M | -2.76M | -22.35% |
| Dec 31, 2020 | 12.36M | 6.57M | 113.56% |
| Dec 31, 2019 | 5.79M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Organogenesis Holdings | 433.14M |
| Procaps Group | 414.10M |
| Tactile Systems Technology | 274.42M |
| Esperion Therapeutics | 116.33M |
| Ocugen | 6.04M |
| Atai Life Sciences | 314.00K |
| Sera Prognostics | 306.00K |
CRBU News
- 11 days ago - Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 20 days ago - Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) - GlobeNewsWire
- 4 weeks ago - Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus - GlobeNewsWire
- 6 weeks ago - HireRight Holdings Corp. (HRT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - Business Wire
- 7 weeks ago - Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Caribou Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024 - GlobeNewsWire
- 5 months ago - Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024 - GlobeNewsWire